Abstract
Momelotinib is a Janus kinase 1/2 inhibitor in clinical development for the treatment of myelofibrosis. Two phase 1 open-label, parallel-group, adapti......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
